Drugs / Rezvilutamide
Trials 30 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05607693 | Apr 2023 → Nov 2024 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04631549 | Feb 2021 → Jul 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04621669 | Jan → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04903158 | Jan → Mar 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04676035 | Jun 2020 → Jan 2022 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04664725 | Jun 2020 → Jan 2021 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02747342 | Sep 2016 → Jun 2019 | prostate cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05928780 | Jul 2023 → Mar 2024 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03741712 | Nov 2018 → Sep 2019 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02691975 | Apr 2016 → Dec 2020 | hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07711314 | Jul 2026 → May 2027 expected | cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT07490210 | May 2026 → May 2032 expected | metastatic prostate carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348264 | Oct 2024 → Mar 2029 expected | salivary duct carcinoma | Peking University First Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06505278 | Aug 2024 → Mar 2025 overdue | prostate cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06387056 | Apr 2024 → Apr 2026 overdue | metastatic prostate carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06134271 | Nov 2023 → Apr 2025 | prostate carcinoma | Jianbin Bi | Unknown | No outcome recorded |
| Phase 2 | NCT06305832 | Sep 2023 → Mar 2028 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT05924256 | Jul 2023 → Dec 2026 expected | salivary gland carcinoma | Fudan University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05753566 | Mar 2023 → Mar 2027 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04603833 | Dec 2020 → Oct 2022 | metastatic prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04102124 | Apr 2019 → Aug 2021 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07241416 | Dec 2025 → Mar 2027 expected | prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05956639 | Jun 2023 → Dec 2025 overdue | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05009290 | Nov 2021 → Sep 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03520478 | May 2018 → Apr 2023 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07444983 | Feb 2026 → Feb 2027 expected | prostate adenocarcinoma | Fujian Medical University Union Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07112209 | Nov 2023 → Jun 2027 expected | metastatic prostate carcinoma | Zhujiang Hospital | Enrolling by invitation | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07407283 Background | Apr 2026 → Nov 2027 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07230106 Background | Dec 2025 → Dec 2028 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06992232 Background | Aug 2024 → Jul 2027 expected | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07611110 Comparator | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05983783 Comparator | Aug 2023 → Dec 2025 overdue | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT06350825 Comparator | Jan 2016 → Dec 2027 expected | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rezvilutamide | “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗21“Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a...” PMID 36075260 ↗ Sep 2022 “Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.” NCT06992232 ↗ “Triplet or doublet therapy (ie. docetaxel/abiraterone, apalutamide，Rezvilutamide，darolutamide，enzalutamide)” NCT06350825 ↗ “6-month course of Rezvilutamide and ADT + chemotherapy” NCT05956639 ↗ |
| Known as | REZ | “The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive...” PMID 39690158 ↗ Dec 2024 |
| Known as | Rezvilutamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650276 ↗ |
| Known as | SHR3680 | “Rezvilutamide (SHR3680), a novel androgen receptor inhibitor independently developed by a Chinese pharmaceutical company” NCT07490210 ↗ |
| Action | Inhibit | “SHR3680 is a novel strong AR antagonist.” NCT02691975 ↗ |
| Modality | Small molecule | — CHEMBL4650276 ↗ |
| Route | Oral | “SHR3680 is administrated orally” NCT02691975 ↗ |
| Target | AR | “SHR3680 is a novel strong AR antagonist.” NCT02691975 ↗ |